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The role of statins in the primary and secondary prevention of cardiovascular
events is well known. An important adverse event associated with statin
treatment is myopathy; intensive physical effort in patients treated with statins
increases the risk of muscle injury/myopathy. In this article we discuss the
benefits and risks associated with statin treatment in patients undergoing
cardiac rehabilitation after acute coronary syndromes and/or coronary
revascularization procedures. In our opinion, the benefits of the secondary
prevention of coronary heart disease achieved with statins seem to outweigh
the hazards associated with statin therapy. The careful selection of patients for
both treatment with statins and the gradual intensification of physical training
in the course of cardiac rehabilitation appears to constitute an important
element of the therapeutic approach.
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Introduction
Physical activity is still an underestimated primary and secondary
prevention factor for the reduction of the risk of acute coronary events.
The aim of cardiac rehabilitation is the shortening of treatment time after
acute coronary syndromes (ACS), the independent functioning and
occupational activity for as many patients as possible, as well as the
prevention of disability and the consequent financial burden on the state
[1]. Data from the “Report of the condition of cardiac rehabilitation in
Poland” in 2004 [2] confirm the high effectiveness of cardiac rehabilitation
in patients with coronary heart disease (CHD). Cardiac rehabilitation may
lower cardiac mortality by 20-25% and the percentage of deaths during
the first year after myocardial infarction (MI) by 35%. 
Most patients after ACS are automatically qualified for statin therapy;
some of them start the treatment at almost the same time as the
beginning of their cardiac rehabilitation. Some studies have reported an
increased prevalence of myopathy in patients under intensive
hyperlipidaemia treatment [3]. Thus, the risk of statin-induced myopathy
should be taken into account in all patients treated with statins with
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The aim of our review article is to emphasize
that apart from the appropriate selection of drugs
and doses, there should be a focus on good
cooperation between the medical team and the
patient. This cooperation would guarantee imme  -
diate reporting of undesirable symptoms, so as to
quickly withdraw the patient from the therapy and
avoid life-threatening complications.
Statins and exercise – good or poor
combination?
Cardiac rehabilitation is a good method of
treatment for patients with stable CHD, with
a history of ACS [4], percutaneous coronary
interventions (PCI) and coronary artery bypass
grafting (CABG). A well-organized programme of
physical training in patients with coronary
dysfunctions has many physiological, biochemical
and haemodynamic benefits.
In Poland a three-stage model of cardiac
rehabilitation is currently used. The first stage is in-
hospital rehabilitation. The second is early cardiac
rehabilitation practised at home, in ambulatory or
stationary conditions. The third stage is late
rehabilitation, undertaken to maintain the effects
of previous treatments and rehabilitation, as well
as to prevent further coronary episodes.
Once the patient leaves the hospital, he is
qualified to begin early cardiac rehabilitation. Its
foundation is rehabilitation based on exercising and
physical training. The essential effect of physical
training is a decrease in the heart rate, both during
rest and at the time of exercise. The effect of
appropriately chosen training is a reduction of the
demand of the heart for oxygen during major
exercise, which decreases the risk of acute heart
ischaemia. It causes regeneration of the vascular
endothelium and, as a result, an increase of
nitrogen oxide production, which widens the
vascular bed. It enables a significant broadening of
the scope of life activities among patients. Physical
efficiency can increase in patients with CHD up to
20-30% by physical rehabilitation. 
The most frequently recommended form of
physical rehabilitation is interval training on
a bicycle ergometer, because it enables precise
control of load, pulse rate and blood pressure and,
if needed, constant observation of heart functioning
on the monitor with a graphic record on an ECG
monitor [5].
Physicians often recommend this kind of
treatment in support of pharmacotherapy, because
the results of early cardiac rehabilitation are
promising: they improve not only the patients’
physical efficiency but also their quality of life. 
Until now, we have only described the positive
effects of increased physical activity in patients
after ACS. However, experience from our clinical
practice and a review of the literature on this topic,
while obviously not negating the undeniable
evidence of the beneficial effects of exercise,
strongly suggest that in some groups of patients
special precautions should be taken, careful
consideration made, and accuracy should be
maintained in informing patients about the
potential side effects of combining two factors:
pharmacotherapy with statins and physical exercise. 
The role of statins in both the prevention of CHD
and after acute coronary episodes has been well
demonstrated in many studies [6]. One of the most
important aims of modern medicine is to lower
cholesterol levels; some researchers call it a medical
obsession [7]. Since statin use has become
common, and especially since their use has been
introduced in recommendations for treatment of
patients after an ACS, reports on substantial side
effects of hyperlipidaemia treatment have appeared,
apart from descriptions of the excellent effectiv  -
eness of these drugs. Due to the benefits of statin
therapy proved in studies, the risk of this therapy
tends to be underestimated. Statins belong to
a group of drugs well tolerated among patients.
They are administered only once a day and they
can be used in monotherapy or as part of
combination treatment [8]. However, they can
provoke various side effects, ranging from dyspeptic
symptoms, through moderately intense pain
ailments, to the most severe ones such as liver
damage and acute cell injury in the muscular
system – rhabdomyolysis [9]. 
The safety of aggressive hyperlipidaemia therapy
has been the subject of many analyses. The results
of the PRIMO (Prediction of Muscular Risk in
Observational Conditions) study, which included
7924 patients with drug therapy of hyperlipidaemia
in various doses, was published in 2005. Muscular
symptoms were observed in 10.49% of patients.
The highest risk was noted in patients taking
simvastatin (18.2%) and the lowest (5.1%) in
patients taking fluvastatin [10]. In earlier studies,
the average frequency of rhabdomyolysis occur  -
rence during monotherapy with atorvastatin,
pravastatin or simvastatin was 0.44, with fibrates
2.82, and with cerivastatin (1st generation statin
which was withdrawn in 2001) 5.34 cases per
100 000 patients per year. This frequency rose to
5.98 if atorvastatin, pravastatin or simvastatin was
used together with fibrates [11]. Based on studies
carried out on healthy people, the frequency of
moderately intense pain ailments is estimated at
190, myopathy with a significant increase in
creatine kinase (CK) level at 5 and rhabdomyolysis
at 1.6 cases per 100 000 patients per year [12].
The frequency of rhabdomyolysis estimated in
various studies is definitely affected by differences
in the definition of this disease. To diagnose
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rhabdomyolysis, the most commonly used criterion
is a sudden increase of serum CK levels exceeding
at least fivefold the upper normal limit after
excluding myocardial infarction (CK-MB fraction 
< 5%) [13]. 
The risk of myotoxicity during hyperlipidaemia
treatment with statins increases during simul  taneous
therapy with drugs impeding statin meta  bolism,
which include itraconazole, erythro  mycin and
nefazodone [14], or others which can cause muscle
inflammation, such as cyclosporine, macrolide
antibiotics, niacin, azole antimycotic drugs, protease
inhibitors or calcium channel blockers [15]. The risk
of statin-induced myopathy is also increased in
electrolyte imbalance, severe infections, injuries and
hypoxia [14], as well as in hepatic disorders and renal
failure [15, 16]. In the last two pathologies, the risk
is related to the dose of statins [17]. Hypothyroidism
may also predispose to rhabdomyolysis [18]. The risk
of myopathy also increases significantly in patients
with congenital muscular defects, in patients with
alcohol-related diseases, in people from the
Mongoloid race and in people consuming large
amounts of grapefruit juice [19]. 
A few articles provide information concerning
life-threatening side effects of simvastatin therapy
[20-22]. A recent topic of discussion is the role of
genetic factors in the occurrence of statin-induced
myopathy, which can influence the pharma  -
cokinetics of these drugs and play a part in causing
metabolic muscular diseases. Gene mutations
responsible for metabolic muscular diseases were
found in 10% of patients with statin-induced
myopathy but only in 3% of patients who tolerated
statins well [23].
Finally, a crucial factor predisposing to rhabdo  -
myolysis in patients undergoing statin therapy is
loading with physical effort [16, 24].
The study of Thompson et al. published in 1997
[25] analysed the hypothesis that physical effort in
the course of statin treatment causes a higher
increase of muscle damage factor activity (CK) 
than physical training in patients who were not
taking these drugs. Fifty-nine men with LDL 
> 130 mg/dl in spite of dietary therapy were
examined. These patients were given 40 mg of
lovastatin or a placebo over a 5-week period.
Moreover, after 4 weeks of therapy, they underwent
a 45-min treadmill test in order to assess maximal
expected heart rate. In the following week, the
patients trained using a different set of exercises.
The activity of CK was examined before and after
physical effort. It was demonstrated that the activity
of CK in the group taking lovastatin was higher by
62% to 77% than in the case of physical training.
Therefore, it was hypothesized that statins intensify
muscle damage connected to physical training. 
In the study published by Coen et al. [26],
physically inactive patients with hypercholes  -
terolaemia were divided into 2 groups. Patients from
both groups received 10 mg of rosuvastatin during
a 20-week period. Additionally, patients from the
first group attended a programme of physical
training between the 10th and 20th week.
A temporary increase of CK activity 48 h after the
first round of exercise was noted in the exercise
group, but these values returned to previous levels
48 h after the fifth round of exercise. Side effects
such as muscular pain and stiffness were observed
very early on, but their occurrence was not
associated with the increase of CK. These results
differ significantly from the results obtained by
Thompson et al. [25], probably due to the smaller
load with physical effort in the new study.
In another study, professional sportsmen with
familial hypercholesterolaemia, taking all sorts of
statins (excluding cerivastatin), were analysed; 
78% of them did not tolerate the suggested statin
therapy because of muscular pain. However, an
increase of CK activity higher than the acceptable
levels for sportsmen was not observed [27]. 
There is no unambiguous answer in the litera  -
ture as to whether the treatment of physical
exercise in the scheme of early cardiac rehabilitation
is safe in patients undergoing therapy with statins.
Does clinical practice offer any hints? 
Although there are almost no data from large
clinical trials about the possible effect of statin
therapy on the whole process of cardiac reha  -
bilitation, some clinical conclusions can be drawn
from case reports. In 2009 we published an article
reporting a case of severe myopathy during therapy
with simvastatin in a patient undergoing early
cardiac rehabilitation after PCI [28]. In the presented
case, a high dose of simvastatin, together with too
intensive physical training in the poorly trained
patient, led to the development of life-threatening
rhabdomyolysis. Our patient also presented 
with abnormal structure of the left kidney in
ultrasonography (post-inflammatory changes? 
renal cirrhosis?) and abnormal kidney function.
These abnormalities might have had a significant
influence on statin metabolism and unfortunately
had not been taken into consideration before the
patient was qualified for the rehabilitation
programme [28].
Conclusions
The careful selection of patients for both
treatment with statins and the gradual intensi  -
fication of physical training in the course of cardiac
rehabilitation appears to be fundamentally impor  -
tant. The general condition and the previous physi  -
cal activity of the patient should be assessed,
together with all the factors presented above that
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can influence the safety of statin therapy. Such
a procedure will help clinicians to achieve the
maximal benefit of cardiac rehabilitation with
minimal risk of serious side effects of simul  -
taneously conducted hyperlipidaemia treat  ment. 
In our opinion, the benefits of the secondary
prevention of CHD achieved with statins seem to
outweigh the hazards of this kind of therapy.
However, the question as to whether patients
taking statins are the best candidates for early
cardiac rehabilitation still remains unanswered. 
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